Xolair, a drug developed 15 years ago by Roche and Novartis, received a breakthrough designation from the US regulator in a new food allergy indication.
Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine tre
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.